The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.
The Union Health Ministry has launched the e-Blood Bank Portal, making it easier for patients and organisers to access blood supply information instantly. Maharashtra leads in blood collection, and ...
Overall, the near-term success of those ambitions will come down to a handful of new drug launches and a sickle cell disease ... Beyond hemophilia, the next frontier for Novo’s blood disorder ...
The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, ...
Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said that oncology and rare ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitliatm (fitusiran), the sixth ...
AB negative – he was considered a ‘universal donor of platelets’ which meant that anyone could receive his platelets without ...
Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space with a vertic.
Asian News International on MSN14d
Bharat Biotech unveils vertically integrated cell, gene therapy, viral production facility at Genome ValleyHyderabad: Bharat Biotech International Limited (BBIL), has announced the launch of India's only vertically integrated, ...
Bharat Biotech on Thursday launched vertically integrated cell and gene therapy ... products for various disease indications, including blood cancers, solid organ cancers, and genetic disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback